JPRN-UMIN000000786已完成2 期
Randomized phase II study of mFOLFOX6 versus TS-1/CPT-11 in patients with advanced/recurrent colorectal cancer - OGSG0702
OGSG0 个研究点目标入组 70 人开始时间: 2007年8月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pulmonary fibrosis or Interstitial Pneumonitis by chet X-ray examination 2)Cavity fluid which needs drainage 3)with active double cancer 4)with peripheral nerve disorder 5)with intestinal paralysis or intestinal obstruction 6)under watery diarrhea 7)uncontrolled DM 8)with mental disorder which disturbs registration to this study 9)with infectious disease 10)patients who receive steroids treatment 11)Cardiac failure, liver dysfunction, or renal dysfunction which disturb Registration to this study 12)with brain metastasis and its symptom 13)pregnant women or women who like to be pregnant 14)history of severe allergy against drug 15)patients receiving Atazanabil 16)doctor's dicision not to be registered to this study
研究者
相似试验
已完成
2 期
Multicenter phase II study of modified FOLFOX6 and bevacizumab in chemonaive advanced or recurrent colorectal cancer.Colorectal CancerJPRN-UMIN000001490Yakult Honsha Co.,Ltd.65
已完成
2 期
Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancercolorectal cancerJPRN-UMIN000003477Chiba Cancer Center Hospital80
已完成
2 期
Randomized Phase II study of SOX vs mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer (KSCC1301)rectal cancerJPRN-UMIN000011486Kyushu Study group of Clinical Cancer(KSCC)110
已完成
2 期
Safety and efficacy of Alternating mFOLFOX6 and FOLFIRI every 4cycles as First line Therapy in Advanced colorectal Cancernresectable advanced/recurrent colorectal cancerJPRN-UMIN000001340KSCC47
招募中
2 期
Multicenter phase II trial of mFOLFOX6 with cetuximab as active chemotherapy regimen for liver metastases inappropriate for curative resection in EGFR positive and KRAS wild type colorectal cancerEGFR positive and KRAS wild type colorectal cancer with liver metastases inappropriate for curative resectionJPRN-UMIN000004683Tohoku - Six Universities Research Group by Experts (T-SURGE)50